Haemonetics Sets Date for Q3 2025 Earnings Release: February 6, 2025

Haemonetics Corporation (NYSE: HAE) has announced that it will publish its third quarter fiscal year 2025 financial results on Thursday, February 6, 2025, at 6:00 am ET. The company will also host a conference call with investors and analysts to discuss the results and answer questions at 8:00 am ET on the same day. The call can be accessed via teleconference or live webcast on Haemonetics' investor relations website.

Haemonetics, a global healthcare company, provides a suite of innovative medical products and solutions for customers, helping them improve patient care and reduce the cost of healthcare. The company's technology addresses important medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services.

In the second quarter of 2025, Haemonetics reported earnings per share (EPS) of $1.12, beating the consensus estimate of $1.09 by $0.03. The company's revenue for the quarter was $345.50 million, compared to the consensus estimate of $342.57 million. Haemonetics has a trailing price-to-earnings ratio of 39.22 and a forward price-to-earnings ratio of 19.14.

Haemonetics has provided guidance for its fiscal year 2025 earnings, with EPS expected to be between $4.45 and $4.75. The company has also issued revenue guidance of $1.4 billion to $1.4 billion for the year. Analysts expect Haemonetics to report EPS of $4.59 for the year, with revenue of $1.4 billion.

Haemonetics' stock price has been volatile in recent months, with shares trading between $70.25 and $97.97. The company's market capitalization is $4.39 billion, and it has a debt-to-equity ratio of 1.39.

Investors will be watching Haemonetics' Q3 2025 earnings release closely to see how the company performed in the quarter and to gain insights into its future prospects. The earnings release and conference call will provide valuable information about Haemonetics' financial health and its plans for growth and expansion.

In conclusion, Haemonetics has set the date for its Q3 2025 earnings release, which will provide investors with important information about the company's financial performance and future prospects. The earnings release and conference call will be closely watched by investors and analysts, who will be looking for insights into Haemonetics' growth and expansion plans.